Canaccord lowered the firm’s price target on DocGo (DCGO) to $1 from $1.50 and keeps a Hold rating on the shares. The firm updated is model following mixed Q4 results as revenue topped the high end of its guidance. DocGo has significant work left to do to scale its go-forward Mobile Health business and rightsize its cost structure to regain adj-EBITDA profitability targeted in 2H 2026. The formal process exploring strategic alternatives may deliver a positive outcome for shareholders, but fundamentally, Canaccord maintains its “show me” stance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- DocGo Earnings Call Signals Turnaround Amid Cash Strain
- DocGo price target lowered to $2.50 from $4 at Stifel
- DocGo: Strengthening Fundamentals and Strategic Positioning Support Buy Rating Despite Near-Term Balance-Sheet Pressures
- DocGo reports FY25 EPS ($1.84), two estimates (60c)
- DCGO Earnings Report this Week: Is It a Buy, Ahead of Earnings?